CD1C Antibody

What is CD1C and what are its key biological characteristics?

CD1C (also called BDCA-1) is a member of the CD1 family of proteins that are structurally related to MHC class I molecules. It is a membrane glycoprotein with a molecular weight of 43 kDa, non-covalently associated with β2-microglobulin. Like other CD1 proteins, CD1C forms heterodimers with β2-macroglobulin and presents lipid antigens on the cell surface to interact with T cells .

CD1C has a distinct structural framework in its ligand-binding pocket compared to other CD1 family members (CD1A, CD1B, CD1D, and CD1E), resulting in different preferences for bound lipids. For example, while CD1D binds the anti-tumor immunostimulant α-galactosylceramide (α-GalCer), CD1C specifically binds the cancer lipid antigen methyl-lysophosphatidic acid (LPA) .

Where is CD1C expressed in human tissues?

CD1C expression follows a specific pattern across immune cell populations and tissues:

• Major subpopulation of human myeloid dendritic cells (designated as type-1 myeloid dendritic cells or MDC1s)

• Subpopulation of CD19+ small resting B lymphocytes in blood

• Cortical thymocytes (weak expression)

• Langerhans cells in skin

• Mature T cells (in a tightly regulated manner)

• Dendritic cells in various tissues including thymus and tonsil

This expression pattern makes CD1C antibodies valuable tools for identifying and isolating specific immune cell subsets, particularly dendritic cell populations.

What are the primary functions of CD1C in immune regulation?

CD1C primarily functions in:

• Antigen presentation of glycolipids to T cells, facilitating immune recognition

• Immune regulatory functions in T cells

• Participation in adaptive immunity mechanisms

• Contribution to tissue homeostasis

• Involvement in autoimmune disease processes

Additionally, CD1C is part of the tumor microenvironment (TME) and participates in immune activity regulation in breast tumors, suggesting its potential as a prognostic marker and therapeutic target in cancer research .

What are the key applications of CD1C antibodies in immunological research?

CD1C antibodies serve multiple critical research applications:

• Flow cytometry for identification and phenotyping of dendritic cell subsets

• Immunohistochemistry for tissue localization studies

• Cell isolation and enrichment techniques using magnetic beads

• Western blot analysis for protein expression quantification

• Immunoprecipitation for protein-protein interaction studies

• Tracking receptor internalization dynamics

• Antigen targeting approaches for immunotherapy research

How can I isolate CD1C+ dendritic cells with high purity for functional studies?

Isolation of CD1C+ dendritic cells requires a two-step approach for optimal purity:

• Initial cell sorting: Use commercial CD1c (BDCA-1)+ Dendritic Cell Isolation Kits that employ a sequential magnetic bead-based isolation strategy:

  • First deplete CD19+ cells using anti-CD19-coated magnetic beads

  • Then positively select CD1c+ cells using biotinylated anti-CD1c antibodies and anti-biotin-beads

• Purity enhancement: Be aware that commercial isolation kits may isolate two functionally different cell populations. For highest purity:

  • Pre-sort cells using the CD1c-isolation kit

  • Follow with FACS-sorting to achieve >97% purity

  • Culture isolated cells in RPMI containing 10% heat-inactivated fetal calf serum, 1% penicillin-streptomycin, and L-glutamine

This approach is critical because monocytes can express CD1c under certain conditions, potentially contaminating your dendritic cell preparation.

What are the optimal antibody clones and protocols for CD1C detection in flow cytometry?

For optimal CD1C detection in flow cytometry:

Protocol recommendations:

• For spectral cytometry panels, start with 1μL of conjugated antibody per sample for most reagents

• Calculate staining indices during panel development to determine optimal concentrations

• Confirm discrimination by signal-to-noise ratio in both single-stain and multicolor "cocktail" staining pilot experiments

• For some reagents like CCR7-BV421, CD11c-eFluor450, CD19-PerCP-Cy5.5, and CD155-PE/Dazzle594, use 2μL per sample for optimal results

How can I assess CD1C internalization dynamics in dendritic cells?

CD1C is rapidly internalized into dendritic cells, which is important for its antigen presentation function. To study this process:

• Internalization assay protocol:

  • Stain single cell suspensions with PE-coupled anti-CLEC10A antibody (a specific marker for CD1c+ DCs)

  • Wash cells and incubate at 37°C for different time points (0, 5, 15, 30, and 60 min)

  • Stain for surface-remaining antibody using an anti-PE secondary antibody and an A647-labeled tertiary antibody

  • Analyze using flow cytometry

• Expected results:

  • In cells kept on ice (0 min), the PE-labeled antibody remains on the surface

  • With increasing incubation time at 37°C, the A647 signal decreases while the PE signal remains stable

  • Significant internalization occurs as early as 5 minutes after incubation at 37°C

This approach allows quantitative assessment of receptor trafficking dynamics, which is crucial for understanding antigen presentation mechanisms.

What are the considerations for validating CD1C antibody specificity?

Validating CD1C antibody specificity is critical for reliable research outcomes:

• Expression system controls:

  • Use CD1C-expressing COS7 cells as a positive control

  • Include appropriate negative controls (CD1C-negative cell lines)

• Tissue controls:

  • Human tonsil, thymus, and skin samples serve as excellent positive controls

  • Verify staining patterns against known expression profiles

• Antibody validation methods:

  • Western blot analysis using anti-CD1C antibody (e.g., ab5, Abcam)

  • qRT-PCR for gene expression correlation with protein detection

  • Cross-validation with multiple antibody clones

• Specificity confirmation:

  • Protein-A affinity chromatography purification ensures >95% purity (by SDS-PAGE)

  • Pre-absorption controls with recombinant CD1C protein

How should I design co-culture experiments to study CD1C+ dendritic cell interactions with T cells?

When designing co-culture experiments to investigate CD1C+ dendritic cell and T cell interactions:

• T cell preparation:

  • Isolate naïve CD4+ T cells using commercial isolation kits (e.g., MACS Naïve CD4+ T cell isolation kit)

  • Stain with CFSE according to manufacturer's instructions for proliferation tracking

• Antigen-presenting cell (APC) preparation:

  • Pre-sort cells on CD1c expression

  • FACS-sort to obtain highly purified subsets

  • Use equal numbers of cells from each subset (4,000–24,500 cells, depending on your experiment)

• Co-culture conditions:

  • Culture APC subsets with naïve CFSE-stained CD4+ T cells at a ratio of 1:5

  • Maintain for 5–6 days in RPMI containing 10% heat-inactivated fetal calf serum, 1% penicillin-streptomycin, and L-glutamine

  • Include T cells alone as a control

• Cytokine analysis:

  • For intracellular staining of cytokines, stimulate co-cultures with 25ng/ml PMA and 250ng/ml ionomycin for 3.5 hours

  • Add 10μg/ml brefeldin A to block secretion

This experimental design allows for functional assessment of CD1C+ dendritic cells' ability to activate and polarize T cell responses.

What approaches are recommended for studying CD1C in tumor microenvironments?

For investigating CD1C in tumor microenvironments, particularly in breast cancer:

• Gene expression analysis:

  • Extract total RNA from tumor tissues and adjacent normal tissues using TRIzol reagent

  • Generate first-strand cDNA using oligo dT primers and reverse transcriptase

  • Perform qRT-PCR using QuantiTect SYBR Green PCR Master Mix and specific primers

  • Calculate expression using the 2-ΔΔCt method

• Protein expression analysis:

  • Freeze tissue samples immediately in liquid nitrogen and store at -80°C

  • Centrifuge at 4°C and 12,000 rpm for 30 minutes

  • Quantify protein using the BCA method

  • Perform Western blot using 12% SDS PAGE gel

  • Use anti-CD1C antibody (e.g., ab5, Abcam) for detection

• Correlation with clinical outcomes:

  • Analyze CD1C expression in relation to patient survival data

  • Correlate with immune infiltration profiles

  • Examine associations with other prognostic markers

This multi-faceted approach provides comprehensive insights into CD1C's role in cancer biology and potential as a prognostic marker.

How can I utilize CD1C antibodies in antigen targeting approaches?

CD1C antibodies can be leveraged for targeted delivery of antigens to dendritic cells:

• Antibody-antigen fusion design:

  • Fuse a receptor-specific antibody (anti-CD1C) with an antigen of choice (viral, bacterial, or cancer antigens)

  • This allows targeted delivery to CD1C+ dendritic cells

• Receptor internalization assessment:

  • Confirm that CD1C undergoes efficient internalization upon antibody binding

  • Use internalization assays as described in question 2.3

  • Rapid internalization (within 5 minutes) makes CD1C an excellent target for antigen delivery

• Delivery validation:

  • Track labeled antigens to confirm delivery to appropriate intracellular compartments

  • Assess processing and presentation efficiency through T cell activation assays

  • Compare with other targeting approaches (e.g., targeting CLEC10A, another marker for CD1C+ DCs)

This approach has significant potential for developing targeted immunotherapies and vaccines.

How should I interpret variations in CD1C expression across different immune cell populations?

When analyzing CD1C expression across immune cell populations:

• Expected expression patterns:

  • Strong expression on myeloid dendritic cells (CD1c+ MDC1s)

  • Moderate expression on a subset of CD19+ B cells

  • Weak expression on cortical thymocytes

  • Expression on Langerhans cells

  • Regulated expression on some mature T cells

• Quantitative analysis approaches:

  • Use mean fluorescence intensity (MFI) differences (MFI CD1C − MFI isotype control)

  • Apply statistical analysis using one-way ANOVA with appropriate post-tests

  • Present data as mean ± SD across multiple donors

• Interpretation guidelines:

  • Consider tissue-specific variations in expression levels

  • Account for activation state of cells (resting vs. stimulated)

  • Correlate expression with functional attributes of the cell populations

Understanding these expression patterns is essential for accurate identification and functional characterization of dendritic cell subsets.

What are the implications of CD1C's relationship with other dendritic cell markers like CLEC10A?

The relationship between CD1C and CLEC10A has important implications for dendritic cell biology:

• Co-expression patterns:

  • CLEC10A is a specific marker for human CD1c+ dendritic cells

  • It provides an additional targeting receptor for CD1c+ DCs

• Functional significance:

  • Both receptors can internalize upon antibody binding

  • CLEC10A shows rapid internalization into CD1c+ DCs, similar to CD1C itself

  • This dual-receptor system provides multiple targeting options for antigen delivery

• Analytical approach:

  • When analyzing flow cytometry data, examine co-expression of CD1C and CLEC10A

  • Compare internalization kinetics of both receptors

  • Assess functional outcomes of targeting either receptor individually or in combination

This relationship offers opportunities for enhanced targeting strategies in immunotherapy development.

How can I analyze CD1C expression in clinical samples for prognostic applications?

For analyzing CD1C expression in clinical samples with prognostic intent:

• Gene expression analysis:

  • Extract RNA from clinical samples and perform qRT-PCR

  • Use validated primer sets (available from manufacturers like Qingke)

  • Calculate expression using the 2-ΔΔCt method relative to housekeeping genes

• Protein expression quantification:

  • Perform Western blot analysis using specific anti-CD1C antibodies

  • Quantify band intensity using image analysis software

  • Normalize to loading controls

• Statistical approaches for clinical correlation:

  • Perform survival analysis (Kaplan-Meier) based on CD1C expression levels

  • Use multivariate Cox regression to assess independent prognostic value

  • Correlate expression with established clinical parameters

• Tissue microarray analysis:

  • Use immunohistochemistry to assess CD1C expression in large patient cohorts

  • Develop scoring systems based on staining intensity and distribution

  • Correlate with patient outcomes and treatment responses

This analytical framework provides robust assessment of CD1C's potential as a prognostic biomarker, particularly in breast cancer and other malignancies.